BOEHRINGER EXEC BROUILLON TELLS REUTERS IT IS NOT CLEAR YET WHETHER SURVODUTIDE, CO-DEVELOPED WITH ZEALAND PHARMA, WILL FIRST BE LAUNCHED AGAINST LIVER DISEASE MASH OR OBESITY
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
622 DKK | +3.84% | +6.60% | +66.67% |
Apr. 04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
Mar. 20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.67% | 5.55B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Boehringer Exec Brouillon Tells Reuters It Is Not Clear Yet Whet…